Methods of generating human cd4+ th2 cells and uses thereof

A method of producing a population of substantially purified CD4+ Th2 lymphocytes, comprising:

• obtaining a population of CD4+ T lymphocytes from a subject;
• purifying a population of CD4+RO+ T cells from the CD4+ T lymphocytes;
• initially stimulating the CD4+ T lymphocytes in a media comprising an anti-CD3 monoclonal antibody, an anti-CD28 monoclonal antibody, about 1000 IU/ml of IL-4, wherein the anti-CD3 monoclonal antibody and the anti-CD28 monoclonal antibody are immobilized on a magnetized solid substrate;
• and
• re-stimulating the T lymphocytes in the media, thereby producing a population of substantially purified CD4+ Th2 lymphocytes, wherein the population of CD4+ Th2 lymphocytes is substantially free of Th1 lymphocytes.

A method of transplanting allogeneic donor immune cells to reconstitute immunity in a recipient having a tumor, comprising:

• depleting at least the recipient's T cells that mediate graft rejection;
• administering to the recipient a therapeutically effective amount of a population of allogeneic cells comprising CD4+ and CD8+ T cells;
• and
• administering to the recipient a therapeutically effective amount of a population of CD4+ Th2 cells, thereby transplanting allogeneic immune cells into the recipient and reconstituting immunity in the recipient.

A method of treating a subject having an autoimmune disorder, comprising:

• depleting at least the subject's T cells that mediate the autoimmune disorder;
• administering to the subject a therapeutically effective amount of autologous peripheral blood cells comprising CD4+ and CD8+ T cells;
• and
• administering to the subject a therapeutically effective amount of autologous CD4+ Th2 cells, wherein the administration of the autologous peripheral blood cells and autologous CD4+ Th2 cells treats the autoimmune disorder.

A method of preventing or limiting rejection of a solid organ in a recipient, comprising:

• depleting at least the recipient's T cells that mediate graft rejection;
• administering to the recipient a therapeutically effective amount of allogeneic peripheral blood cells comprising stem cells, CD4+ cells, and CD8+ cells;
• administering to the recipient a therapeutically effective amount of CD4+ Th2 cells;
• and
• transplanting a solid organ into the recipient, wherein the solid organ is HLA-matched to the CD4+ Th2 cells and the allogeneic peripheral blood cells, wherein administration of the allogeneic peripheral blood cells and the allogeneic CD4+ Th2 results in preventing or limiting rejection of the solid organ.